ID   HEM0_HUMAN              Reviewed;         587 AA.
AC   P22557; A8K3F0; A8K6C4; Q13735; Q5JZF5; Q8N6H3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 2.
DT   12-APR-2017, entry version 184.
DE   RecName: Full=5-aminolevulinate synthase, erythroid-specific, mitochondrial;
DE            Short=ALAS-E;
DE            EC=2.3.1.37;
DE   AltName: Full=5-aminolevulinic acid synthase 2;
DE   AltName: Full=Delta-ALA synthase 2;
DE   AltName: Full=Delta-aminolevulinate synthase 2;
DE   Flags: Precursor;
GN   Name=ALAS2; Synonyms=ALASE, ASB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2263504; DOI=10.1093/nar/18.23.7187;
RA   Bishop D.F.;
RT   "Two different genes encode delta-aminolevulinate synthase in humans:
RT   nucleotide sequences of cDNAs for the housekeeping and erythroid
RT   genes.";
RL   Nucleic Acids Res. 18:7187-7188(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2050125;
RA   Cox T.C., Bawden M.J., Martin A., May B.K.;
RT   "Human erythroid 5-aminolevulinate synthase: promoter analysis and
RT   identification of an iron-responsive element in the mRNA.";
RL   EMBO J. 10:1891-1902(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9642238; DOI=10.1074/jbc.273.27.16798;
RA   Surinya K.H., Cox T.C., May B.K.;
RT   "Identification and characterization of a conserved erythroid-specific
RT   enhancer located in intron 8 of the human 5-aminolevulinate synthase 2
RT   gene.";
RL   J. Biol. Chem. 273:16798-16809(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung, Placenta, and Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   ALTERNATIVE SPLICING, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY,
RP   TRANSIT PEPTIDE CLEAVAGE SITE, AND INTERACTION WITH SUCLA2.
RX   PubMed=14643893; DOI=10.1016/S1357-2725(03)00246-2;
RA   Cox T.C., Sadlon T.J., Schwarz Q.P., Matthews C.S., Wise P.D.,
RA   Cox L.L., Bottomley S.S., May B.K.;
RT   "The major splice variant of human 5-aminolevulinate synthase-2
RT   contributes significantly to erythroid heme biosynthesis.";
RL   Int. J. Biochem. Cell Biol. 36:281-295(2004).
RN   [9]
RP   VARIANT SIDBA1 SER-388.
RX   PubMed=8107717; DOI=10.1056/NEJM199403103301004;
RA   Cox T.C., Bottomley S.S., Wiley J.S., Bawden M.J., Matthews C.S.,
RA   May B.K.;
RT   "X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-
RT   to-Ser substitution in erythroid 5-aminolevulinate synthase.";
RL   N. Engl. J. Med. 330:675-679(1994).
RN   [10]
RP   VARIANT SIDBA1 ASN-476.
RX   PubMed=1570328; DOI=10.1073/pnas.89.9.4028;
RA   Cotter P.D., Baumann M., Bishop D.F.;
RT   "Enzymatic defect in 'X-linked' sideroblastic anemia: molecular
RT   evidence for erythroid delta-aminolevulinate synthase deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4028-4032(1992).
RN   [11]
RP   VARIANT SIDBA1 CYS-411.
RX   PubMed=9858242; DOI=10.1046/j.1365-2141.1998.01050.x;
RA   Furuyama K., Uno R., Urabe A., Hayashi N., Fujita H., Kondo M.,
RA   Sassa S., Yamamoto M.;
RT   "R411C mutation of the ALAS2 gene encodes a pyridoxine-responsive
RT   enzyme with low activity.";
RL   Br. J. Haematol. 103:839-841(1998).
RN   [12]
RP   VARIANT SIDBA1 GLN-204.
RX   PubMed=10577279;
RX   DOI=10.1002/(SICI)1096-8652(199910)62:2<112::AID-AJH9>3.0.CO;2-L;
RA   Harigae H., Furuyama K., Kudo K., Hayashi N., Yamamoto M., Sassa S.,
RA   Sasaki T.;
RT   "A novel mutation of the erythroid-specific gamma-aminolevulinate
RT   synthase gene in a patient with non-inherited pyridoxine-responsive
RT   sideroblastic anemia.";
RL   Am. J. Hematol. 62:112-114(1999).
RN   [13]
RP   VARIANTS SIDBA1 HIS-199; CYS-411; GLN-448 AND CYS-452.
RX   PubMed=10029606;
RA   Cotter P.D., May A., Li L., Al-Sabah A.I., Fitzsimons E.J.,
RA   Cazzola M., Bishop D.F.;
RT   "Four new mutations in the erythroid-specific 5-aminolevulinate
RT   synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased
RT   pyridoxine responsiveness after removal of iron overload by phlebotomy
RT   and coinheritance of hereditary hemochromatosis.";
RL   Blood 93:1757-1769(1999).
RN   [14]
RP   VARIANT SIDBA1 HIS-560.
RX   PubMed=12393718; DOI=10.1182/blood-2002-03-0685;
RA   Cazzola M., May A., Bergamaschi G., Cerani P., Ferrillo S.,
RA   Bishop D.F.;
RT   "Absent phenotypic expression of X-linked sideroblastic anemia in one
RT   of 2 brothers with a novel ALAS2 mutation.";
RL   Blood 100:4236-4238(2002).
RN   [15]
RP   VARIANT SIDBA1 TYR-159.
RX   PubMed=12031592; DOI=10.1016/S0009-8981(02)00095-5;
RA   Hurford M.T., Marshall-Taylor C., Vicki S.L., Zhou J.Z.,
RA   Silverman L.M., Rezuke W.N., Altman A., Tsongalis G.J.;
RT   "A novel mutation in exon 5 of the ALAS2 gene results in X-linked
RT   sideroblastic anemia.";
RL   Clin. Chim. Acta 321:49-53(2002).
RN   [16]
RP   INVOLVEMENT IN XLDPT.
RX   PubMed=18760763; DOI=10.1016/j.ajhg.2008.08.003;
RA   Whatley S.D., Ducamp S., Gouya L., Grandchamp B., Beaumont C.,
RA   Badminton M.N., Elder G.H., Holme S.A., Anstey A.V., Parker M.,
RA   Corrigall A.V., Meissner P.N., Hift R.J., Marsden J.T., Ma Y.,
RA   Mieli-Vergani G., Deybach J.C., Puy H.;
RT   "C-terminal deletions in the ALAS2 gene lead to gain of function and
RT   cause X-linked dominant protoporphyria without anemia or iron
RT   overload.";
RL   Am. J. Hum. Genet. 83:408-414(2008).
RN   [17]
RP   VARIANTS SIDBA1 LEU-165; CYS-170; ALA-301; CYS-411; GLY-452; GLY-517
RP   AND LEU-520.
RX   PubMed=19731322; DOI=10.1002/pbc.22244;
RA   Bergmann A.K., Campagna D.R., McLoughlin E.M., Agarwal S.,
RA   Fleming M.D., Bottomley S.S., Neufeld E.J.;
RT   "Systematic molecular genetic analysis of congenital sideroblastic
RT   anemia: evidence for genetic heterogeneity and identification of novel
RT   mutations.";
RL   Pediatr. Blood Cancer 54:273-278(2010).
RN   [18]
RP   VARIANTS SIDBA1 GLU-156; CYS-452 AND HIS-452, AND CHARACTERIZATION OF
RP   VARIANT SIDBA1 GLU-156.
RX   PubMed=21252495; DOI=10.1159/000322870;
RA   Kucerova J., Horvathova M., Mojzikova R., Belohlavkova P., Cermak J.,
RA   Divoky V.;
RT   "New mutation in erythroid-specific delta-aminolevulinate synthase as
RT   the cause of X-linked sideroblastic anemia responsive to pyridoxine.";
RL   Acta Haematol. 125:193-197(2011).
RN   [19]
RP   VARIANT PHE-586, CHARACTERIZATION OF VARIANT PHE-586, AND POSSIBLE
RP   ROLE AS MODIFIER GENE IN ERYTHROPOIETIC DISORDERS.
RX   PubMed=21653323; DOI=10.1182/blood-2011-03-342873;
RA   To-Figueras J., Ducamp S., Clayton J., Badenas C., Delaby C., Ged C.,
RA   Lyoumi S., Gouya L., de Verneuil H., Beaumont C., Ferreira G.C.,
RA   Deybach J.C., Herrero C., Puy H.;
RT   "ALAS2 acts as a modifier gene in patients with congenital
RT   erythropoietic porphyria.";
RL   Blood 118:1443-1451(2011).
RN   [20]
RP   VARIANTS SIDBA1 HIS-170; HIS-218; LYS-242; ASN-263; LEU-339; CYS-375;
RP   HIS-411; GLY-452 AND HIS-572, VARIANT LEU-520, AND CHARACTERIZATION OF
RP   VARIANTS SIDBA1 HIS-170; HIS-218; LYS-242; ASN-263; LEU-339; CYS-375;
RP   HIS-411; GLY-452 AND HIS-572.
RX   PubMed=21309041; DOI=10.1002/humu.21455;
RA   Ducamp S., Kannengiesser C., Touati M., Garcon L., Guerci-Bresler A.,
RA   Guichard J.F., Vermylen C., Dochir J., Poirel H.A., Fouyssac F.,
RA   Mansuy L., Leroux G., Tertian G., Girot R., Heimpel H., Matthes T.,
RA   Talbi N., Deybach J.C., Beaumont C., Puy H., Grandchamp B.;
RT   "Sideroblastic anemia: molecular analysis of the ALAS2 gene in a
RT   series of 29 probands and functional studies of 10 missense
RT   mutations.";
RL   Hum. Mutat. 32:590-597(2011).
CC   -!- CATALYTIC ACTIVITY: Succinyl-CoA + glycine = 5-aminolevulinate +
CC       CoA + CO(2). {ECO:0000269|PubMed:14643893}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; 5-aminolevulinate from glycine: step 1/1.
CC   -!- SUBUNIT: Homodimer. Interacts with SUCLA2.
CC       {ECO:0000269|PubMed:14643893}.
CC   -!- INTERACTION:
CC       Q8N9N5:BANP; NbExp=3; IntAct=EBI-2115743, EBI-744695;
CC       Q8N9N5-2:BANP; NbExp=5; IntAct=EBI-12257000, EBI-11524452;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:14643893}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P22557-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta4;
CC         IsoId=P22557-2; Sequence=VSP_042852;
CC         Note=Constitutes 35-45% of erythrocytes ALAS2 mRNAs. Catalytic
CC         activity is 70% of isoform 1 activity.;
CC       Name=3; Synonyms=F143M;
CC         IsoId=P22557-3; Sequence=VSP_042851, VSP_042853;
CC         Note=Catalytic activity is 80% of isoform 1 activity.;
CC       Name=4;
CC         IsoId=P22557-4; Sequence=VSP_047330, VSP_042852;
CC   -!- TISSUE SPECIFICITY: Erythroid specific.
CC   -!- DISEASE: Anemia, sideroblastic, 1 (SIDBA1) [MIM:300751]: A form of
CC       sideroblastic anemia that shows a variable hematologic response to
CC       pharmacologic doses of pyridoxine. Sideroblastic anemia is
CC       characterized by anemia of varying severity, hypochromic
CC       peripheral erythrocytes, systemic iron overload secondary to
CC       chronic ineffective erythropoiesis, and the presence of bone
CC       marrow ringed sideroblasts. Sideroblasts are characterized by
CC       iron-loaded mitochondria clustered around the nucleus.
CC       {ECO:0000269|PubMed:10029606, ECO:0000269|PubMed:10577279,
CC       ECO:0000269|PubMed:12031592, ECO:0000269|PubMed:12393718,
CC       ECO:0000269|PubMed:1570328, ECO:0000269|PubMed:19731322,
CC       ECO:0000269|PubMed:21252495, ECO:0000269|PubMed:21309041,
CC       ECO:0000269|PubMed:8107717, ECO:0000269|PubMed:9858242}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Erythropoietic protoporphyria, X-linked dominant (XLDPT)
CC       [MIM:300752]: A form of porphyria. Porphyrias are inherited
CC       defects in the biosynthesis of heme, resulting in the accumulation
CC       and increased excretion of porphyrins or porphyrin precursors.
CC       They are classified as erythropoietic or hepatic, depending on
CC       whether the enzyme deficiency occurs in red blood cells or in the
CC       liver. XLDPT is characterized biochemically by a high proportion
CC       of zinc-protoporphyrin in erythrocytes, in which a mismatch
CC       between protoporphyrin production and the heme requirement of
CC       differentiating erythroid cells leads to overproduction of
CC       protoporphyrin in amounts sufficient to cause photosensitivity and
CC       liver disease. {ECO:0000269|PubMed:18760763}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC       Gain of function mutations in ALS2 are responsible for XLDPT, but
CC       they can also be a possible aggravating factor in congenital
CC       erythropoietic porphyria and other erythropoietic disorders caused
CC       by mutations in other genes (PubMed:21309041).
CC       {ECO:0000269|PubMed:21309041}.
CC   -!- MISCELLANEOUS: There are two delta-ALA synthases in vertebrates:
CC       an erythroid- specific form and one (housekeeping) which is
CC       expressed in all tissues.
CC   -!- SIMILARITY: Belongs to the class-II pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA39795.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56352; CAA39795.1; ALT_INIT; mRNA.
DR   EMBL; X60364; CAA42916.1; -; mRNA.
DR   EMBL; AF068624; AAC39838.1; -; Genomic_DNA.
DR   EMBL; AK290565; BAF83254.1; -; mRNA.
DR   EMBL; AK291589; BAF84278.1; -; mRNA.
DR   EMBL; AK313118; BAG35939.1; -; mRNA.
DR   EMBL; Z83821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL020991; CAA15886.1; -; Genomic_DNA.
DR   EMBL; AL020991; CAX15017.1; -; Genomic_DNA.
DR   EMBL; CH471154; EAW93211.1; -; Genomic_DNA.
DR   EMBL; CH471154; EAW93213.1; -; Genomic_DNA.
DR   EMBL; BC030230; AAH30230.2; -; mRNA.
DR   CCDS; CCDS14366.1; -. [P22557-1]
DR   CCDS; CCDS35303.1; -. [P22557-2]
DR   CCDS; CCDS43960.1; -. [P22557-4]
DR   PIR; S16347; SYHUAE.
DR   RefSeq; NP_000023.2; NM_000032.4. [P22557-1]
DR   RefSeq; NP_001033056.1; NM_001037967.3. [P22557-2]
DR   RefSeq; NP_001033057.1; NM_001037968.3. [P22557-4]
DR   UniGene; Hs.522666; -.
DR   UniGene; Hs.555936; -.
DR   ProteinModelPortal; P22557; -.
DR   SMR; P22557; -.
DR   BioGrid; 106714; 3.
DR   IntAct; P22557; 2.
DR   STRING; 9606.ENSP00000332369; -.
DR   DrugBank; DB00145; Glycine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; P22557; -.
DR   PhosphoSitePlus; P22557; -.
DR   BioMuta; ALAS2; -.
DR   DMDM; 20141346; -.
DR   MaxQB; P22557; -.
DR   PaxDb; P22557; -.
DR   PeptideAtlas; P22557; -.
DR   PRIDE; P22557; -.
DR   Ensembl; ENST00000330807; ENSP00000332369; ENSG00000158578. [P22557-1]
DR   Ensembl; ENST00000335854; ENSP00000337131; ENSG00000158578. [P22557-2]
DR   Ensembl; ENST00000396198; ENSP00000379501; ENSG00000158578. [P22557-4]
DR   GeneID; 212; -.
DR   KEGG; hsa:212; -.
DR   UCSC; uc004dua.4; human. [P22557-1]
DR   CTD; 212; -.
DR   DisGeNET; 212; -.
DR   GeneCards; ALAS2; -.
DR   GeneReviews; ALAS2; -.
DR   HGNC; HGNC:397; ALAS2.
DR   HPA; HPA001638; -.
DR   MalaCards; ALAS2; -.
DR   MIM; 300751; phenotype.
DR   MIM; 300752; phenotype.
DR   MIM; 301300; gene.
DR   neXtProt; NX_P22557; -.
DR   OpenTargets; ENSG00000158578; -.
DR   Orphanet; 79278; Erythropoietic protoporphyria.
DR   Orphanet; 75563; X-linked sideroblastic anemia.
DR   PharmGKB; PA24689; -.
DR   eggNOG; KOG1360; Eukaryota.
DR   eggNOG; COG0156; LUCA.
DR   GeneTree; ENSGT00530000063111; -.
DR   HOGENOM; HOG000221020; -.
DR   HOVERGEN; HBG005954; -.
DR   InParanoid; P22557; -.
DR   KO; K00643; -.
DR   OMA; NFPFAEH; -.
DR   OrthoDB; EOG091G043U; -.
DR   PhylomeDB; P22557; -.
DR   TreeFam; TF300724; -.
DR   BioCyc; MetaCyc:HS08311-MONOMER; -.
DR   BRENDA; 2.3.1.37; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   UniPathway; UPA00251; UER00375.
DR   ChiTaRS; ALAS2; human.
DR   GeneWiki; ALAS2; -.
DR   GenomeRNAi; 212; -.
DR   PRO; PR:P22557; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000158578; -.
DR   CleanEx; HS_ALAS2; -.
DR   ExpressionAtlas; P22557; baseline and differential.
DR   Genevisible; P22557; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0003870; F:5-aminolevulinate synthase activity; IDA:UniProtKB.
DR   GO; GO:0050662; F:coenzyme binding; ISS:UniProtKB.
DR   GO; GO:0016594; F:glycine binding; ISS:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0006783; P:heme biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0042541; P:hemoglobin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0032364; P:oxygen homeostasis; NAS:UniProtKB.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR010961; 4pyrrol_synth_NH2levulA_synth.
DR   InterPro; IPR015118; 5aminolev_synth_preseq.
DR   InterPro; IPR001917; Aminotrans_II_pyridoxalP_BS.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   Pfam; PF09029; Preseq_ALAS; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   TIGRFAMs; TIGR01821; 5aminolev_synth; 1.
DR   PROSITE; PS00599; AA_TRANSFER_CLASS_2; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Complete proteome;
KW   Disease mutation; Heme biosynthesis; Mitochondrion;
KW   Pyridoxal phosphate; Reference proteome; Transferase; Transit peptide.
FT   TRANSIT       1     49       Mitochondrion.
FT                                {ECO:0000269|PubMed:14643893}.
FT   CHAIN        50    587       5-aminolevulinate synthase, erythroid-
FT                                specific, mitochondrial.
FT                                /FTId=PRO_0000001223.
FT   ACT_SITE    391    391       {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     163    163       Substrate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     280    280       Substrate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     299    299       Substrate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     332    332       Pyridoxal phosphate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     360    360       Pyridoxal phosphate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     388    388       Pyridoxal phosphate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     420    420       Pyridoxal phosphate; shared with dimeric
FT                                partner. {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     421    421       Pyridoxal phosphate; shared with dimeric
FT                                partner. {ECO:0000250|UniProtKB:P18079}.
FT   BINDING     508    508       Substrate.
FT                                {ECO:0000250|UniProtKB:P18079}.
FT   MOD_RES     391    391       N6-(pyridoxal phosphate)lysine.
FT                                {ECO:0000250|UniProtKB:P08680}.
FT   VAR_SEQ       1    142       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_042851.
FT   VAR_SEQ       1      1       M -> MRGGEVALGWNKKKRLFCEDFRFKM (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_047330.
FT   VAR_SEQ     102    138       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042852.
FT   VAR_SEQ     143    143       F -> M (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_042853.
FT   VARIANT     156    156       K -> E (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21252495}.
FT                                /FTId=VAR_066232.
FT   VARIANT     159    159       D -> Y (in SIDBA1; dbSNP:rs137852308).
FT                                {ECO:0000269|PubMed:12031592}.
FT                                /FTId=VAR_018604.
FT   VARIANT     165    165       F -> L (in SIDBA1; dbSNP:rs137852301).
FT                                {ECO:0000269|PubMed:19731322}.
FT                                /FTId=VAR_072328.
FT   VARIANT     170    170       R -> C (in SIDBA1).
FT                                {ECO:0000269|PubMed:19731322}.
FT                                /FTId=VAR_072329.
FT   VARIANT     170    170       R -> H (in SIDBA1; significantly
FT                                increased thermosensitivity).
FT                                {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066233.
FT   VARIANT     199    199       Y -> H (in SIDBA1; dbSNP:rs137852310).
FT                                {ECO:0000269|PubMed:10029606}.
FT                                /FTId=VAR_012334.
FT   VARIANT     204    204       R -> Q (in SIDBA1; 15% to 35% activity of
FT                                wild-type).
FT                                {ECO:0000269|PubMed:10577279}.
FT                                /FTId=VAR_012335.
FT   VARIANT     218    218       R -> H (in SIDBA1; significantly
FT                                increased thermosensitivity;
FT                                dbSNP:rs185504937).
FT                                {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066234.
FT   VARIANT     242    242       E -> K (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066235.
FT   VARIANT     263    263       D -> N (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066236.
FT   VARIANT     301    301       V -> A (in SIDBA1).
FT                                {ECO:0000269|PubMed:19731322}.
FT                                /FTId=VAR_072330.
FT   VARIANT     339    339       P -> L (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066237.
FT   VARIANT     375    375       R -> C (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066238.
FT   VARIANT     388    388       T -> S (in SIDBA1; dbSNP:rs137852300).
FT                                {ECO:0000269|PubMed:8107717}.
FT                                /FTId=VAR_000562.
FT   VARIANT     411    411       R -> C (in SIDBA1; 12% to 25% activity of
FT                                wild-type; dbSNP:rs137852305).
FT                                {ECO:0000269|PubMed:10029606,
FT                                ECO:0000269|PubMed:19731322,
FT                                ECO:0000269|PubMed:9858242}.
FT                                /FTId=VAR_000563.
FT   VARIANT     411    411       R -> H (in SIDBA1; significantly reduced
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066239.
FT   VARIANT     448    448       R -> Q (in SIDBA1).
FT                                {ECO:0000269|PubMed:10029606}.
FT                                /FTId=VAR_012336.
FT   VARIANT     452    452       R -> C (in SIDBA1; dbSNP:rs137852311).
FT                                {ECO:0000269|PubMed:10029606,
FT                                ECO:0000269|PubMed:21252495}.
FT                                /FTId=VAR_012337.
FT   VARIANT     452    452       R -> G (in SIDBA1; does not affect
FT                                activity). {ECO:0000269|PubMed:19731322,
FT                                ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066240.
FT   VARIANT     452    452       R -> H (in SIDBA1; dbSNP:rs863223904).
FT                                {ECO:0000269|PubMed:21252495}.
FT                                /FTId=VAR_066241.
FT   VARIANT     476    476       I -> N (in SIDBA1; dbSNP:rs137852299).
FT                                {ECO:0000269|PubMed:1570328}.
FT                                /FTId=VAR_000564.
FT   VARIANT     517    517       R -> G (in SIDBA1).
FT                                {ECO:0000269|PubMed:19731322}.
FT                                /FTId=VAR_072331.
FT   VARIANT     520    520       P -> L (in SIDBA1; dbSNP:rs201062903).
FT                                {ECO:0000269|PubMed:19731322,
FT                                ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066242.
FT   VARIANT     560    560       R -> H (in SIDBA1).
FT                                {ECO:0000269|PubMed:12393718}.
FT                                /FTId=VAR_018605.
FT   VARIANT     572    572       R -> H (in SIDBA1; does not affect
FT                                activity). {ECO:0000269|PubMed:21309041}.
FT                                /FTId=VAR_066243.
FT   VARIANT     586    586       Y -> F (rare variant found in a
FT                                congenital erythropoietic porphyria
FT                                patient that also carries UROS mutations
FT                                R-73 and Q-248; increased enzyme
FT                                activity; dbSNP:rs139596860).
FT                                {ECO:0000269|PubMed:21653323}.
FT                                /FTId=VAR_066244.
FT   CONFLICT    182    182       S -> F (in Ref. 1; CAA39795).
FT                                {ECO:0000305}.
FT   CONFLICT    221    221       A -> V (in Ref. 7; AAH30230).
FT                                {ECO:0000305}.
SQ   SEQUENCE   587 AA;  64633 MW;  FD821BE245C440B5 CRC64;
     MVTAAMLLQC CPVLARGPTS LLGKVVKTHQ FLFGIGRCPI LATQGPNCSQ IHLKATKAGG
     DSPSWAKGHC PFMLSELQDG KSKIVQKAAP EVQEDVKAFK TDLPSSLVSV SLRKPFSGPQ
     EQEQISGKVT HLIQNNMPGN YVFSYDQFFR DKIMEKKQDH TYRVFKTVNR WADAYPFAQH
     FSEASVASKD VSVWCSNDYL GMSRHPQVLQ ATQETLQRHG AGAGGTRNIS GTSKFHVELE
     QELAELHQKD SALLFSSCFV ANDSTLFTLA KILPGCEIYS DAGNHASMIQ GIRNSGAAKF
     VFRHNDPDHL KKLLEKSNPK IPKIVAFETV HSMDGAICPL EELCDVSHQY GALTFVDEVH
     AVGLYGSRGA GIGERDGIMH KIDIISGTLG KAFGCVGGYI ASTRDLVDMV RSYAAGFIFT
     TSLPPMVLSG ALESVRLLKG EEGQALRRAH QRNVKHMRQL LMDRGLPVIP CPSHIIPIRV
     GNAALNSKLC DLLLSKHGIY VQAINYPTVP RGEELLRLAP SPHHSPQMME DFVEKLLLAW
     TAVGLPLQDV SVAACNFCRR PVHFELMSEW ERSYFGNMGP QYVTTYA
//
